Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T cell infiltrate in the bone marrow

Dhruv Bansal, Kiran Vij, Gue Su Chang, Christopher A. Miller, John F. DiPersio, Ravi Vij, Sharon E. Heath, Peter Westervelt, John S. Welch, and Todd A. Fehniger

Disclosures: TAF and RV through Washington University have received funding for this clinical trial and correlative science research from Celgene. The authors declare no other conflicts of interest.

Contributions: KV analyzed morphologic bone marrow samples. GSC and CAM performed and analyzed the sequencing. JFD, RV, SEH, PW, and TAF collected samples and provided patient care. TAF and JSW designed and supervised the study analysis. The manuscript was written by DB, TAF, and JSW. All authors contributed in manuscript review, and approved the final version of the manuscript.